Intrinsiqq
Quoin Pharmaceuticals Ltd. logo

Quoin Pharmaceuticals Ltd. Quality Score

QNRX

Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-0.7x

Negative earnings, no valuation support

Business Quality & Capital Allocation

Share Dilution
0/100
2015.1%

Heavy dilution above 5%

Capital Structure
100/100
-$33M

Net cash position, no leverage concern

2020
$323832
$0.00
2021
$7.00M
$0.00
TTM
$33.0M
$0.00
CashDebt
Customize WeightsPremiumUpgrade

Quoin Pharmaceuticals (QNRX) quality: score, margins and returns

Quoin Pharmaceuticals (QNRX) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 2 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Quoin Pharmaceuticals (QNRX) a high-quality business?+

Quoin Pharmaceuticals scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 2 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Quoin Pharmaceuticals's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from QNRX's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Quoin Pharmaceuticals scores well and where it falls behind.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 5 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 12 Nov 2026. How this is calculated.

Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with QNRX

CompareIntrinsic value
LPCNLipocine Inc.
$1.50+0.00%40
IGCIGC Pharma Inc.
$0.17-5.56%26
FLNAFilana Therapeutics, Inc.
$0.64+14.29%40
ETSTEarth Science Tech Inc.
$0.09-2.16%66
CRVOCervoMed Inc.
$1.45+8.65%10
SCYXScynexis, Inc.
$2.38-8.64%40
ELTXElicio Therapeutics Inc.
$1.45-3.33%25
TENXTenax Therapeutics Inc.
$1.29-7.55%10

Spot a number that looks wrong? Check it in QNRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing QNRX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.